FDA Inspection 1303390 — Biomat USA Inc
The FDA completed an inspection of Biomat USA Inc on February 12, 2026 in Chicago, IL. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Biologics.
Inspection Details
- Classification
- No Action Indicated (NAI) (NAI)
- End Date
- February 12, 2026
- Fiscal Year
- 2026
- Product Type
- Biologics
- Project Area
- Blood and Blood Products
- Location
- Chicago, IL (United States)